Teewinot Capital Advisers’s iShares Biotechnology ETF IBB Stock Holding History

Teewinot Capital Advisers’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-30,000	Closed	-$3.03M	–	54
2015 Q3	$3.03M	Buy	+30,000	New	+$3.6M	2.15%	15

Other funds holding IBB

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Teewinot Capital Advisers's IBB Position: Q4 2015 in Review

Teewinot Capital Advisers sold out of iShares Biotechnology ETF (IBB) in Q4 2015, closing a stake of 30,000 shares — an estimated $3.03M sold.

Teewinot Capital Advisers first reported a position in IBB in Q3 2015 and held it in 1 quarter. The position peaked at $3.03M in Q3 2015. 432 funds tracked by Wall St. Rank hold IBB as of Q4 2015.

Teewinot Capital Advisers reported no remaining iShares Biotechnology ETF position as of Q4 2015 after selling out during the quarter.
Teewinot Capital Advisers sold 30,000 iShares Biotechnology ETF shares in Q4 2015, an estimated $3.03M.
Teewinot Capital Advisers first reported a position in iShares Biotechnology ETF in Q3 2015 and held it in 1 quarter.
Teewinot Capital Advisers's iShares Biotechnology ETF position peaked at $3.03M in Q3 2015.
432 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2015.

Based on Teewinot Capital Advisers's 13F filing for Q4 2015, filed 16 Feb 2016.